Loading
A phase 3 trial of Belinostat and Pralatrexate in peripheral T-cell lymphomas, run by Acrotech Biopharma Inc., now recruiting.
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL is a phase 3 interventional study registered as NCT06072131 by Acrotech Biopharma Inc., with 504 participants planned, started 2023-10-04 and due to reach its primary completion in 2030-07. Interventions recorded: Belinostat Injection, Pralatrexate Injection, CHOP and COP.
Shares Belinostat, Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.